Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
NEW ORLEANS, Oct. 28, 2016 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 26, 2016 to file lead plaintiff applications in a securities class action lawsuit against Taro Pharmaceutical Industries Ltd. (NYSE:TARO), if they purchased the Company’s securities between July 3, 2014 and September 9, 2016, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
What You May Do
If you purchased shares of Taro and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by December 26, 2016.
About the Lawsuit
Taro and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On September 9, 2016, Taro announced that its subsidiary and two senior officers received grand jury subpoenas from the U.S. DOJ, Antitrust Division, seeking documents regarding the sale of generic pharmaceutical products.
Then, on October 17, 2016, NECA-IBEW Welfare Trust Fund filed an antitrust class action lawsuit against Taro and several other pharmaceutical companies alleging that they engaged in the price-fixing of Clobetasol since 2014 in violation of the U.S. antitrust laws.
On this news, the price of Taro’s shares plummeted.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
